Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
Open Access
- 7 June 2014
- journal article
- case report
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 126
Abstract
Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in patients with concomitant cardiological disease, especially within the pulmonary circulation, is rare.Keywords
This publication has 14 references indexed in Scilit:
- Management of fingolimod in clinical practiceClinical Neurology and Neurosurgery, 2013
- Cardiovascular autonomic testing in extrapyramidal disordersJournal of the Neurological Sciences, 2011
- Delayed fingolimod-associated asystoleMultiple Sclerosis Journal, 2011
- Sphingosine-1-phosphate augments agonist-mediated contraction in the bronchial smooth muscles of micePharmacological Reports, 2011
- Systemic Administration of Sphingosine-1-Phosphate Increases Bronchial Hyperresponsiveness in the MouseAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2009
- Sphingolipid signalling in the cardiovascular system: Good, bad or both?European Journal of Pharmacology, 2008
- FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosisExpert Opinion on Investigational Drugs, 2007
- Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1PCardiovascular Research, 2003